A study presented at The American Society of Tropical Medicine and Hygiene’s 59th Annual Meeting, has demonstrated that Resveratrol can help to fight malaria. This has raised hopes that a new vaccination will be possible to combat the illness that claims over a million victims every year.
The National Institutes of Health study claims that treatment of red blood cells infected by malaria, with resveratrol and anti-malarial drugs, significantly reduces its ability to bind to the body's cells and blood vessels. This, they indicate, results in a lower chance of developing a severe case of malaria.
Malaria is a mosquito-borne infectious disease which is widespread in tropical and subtropical regions, including parts of the Americas, Asia, and Africa.
In humans, the parasites travel to the liver, where over a period of months, weeks or even years, enter the bloodstream and infect red blood cells. Some of its symptoms include fevers, vomiting, anemia and convulsions and can result in death if not treated properly.
James Betz, founder of world leading resveratrol firm, Biotivia said: “These results are very encouraging to hear as we have entered into a collaboration with the University of Ferrara to investigate the potential therapeutic effects of our proprietary Resveratrol, Transmax, on Beta Thalasemmia patients.”
Thalasemmia is prevalent in areas where malaria is concentrated and gives a degree of protection against the parasitic disease although it is a debilitating disease in its own right. It is an inherited blood disease which is a genetic defect that results in reduced rate of synthesis or no synthesis of one of the globin chains that make up hemoglobin. This can cause the formation of abnormal hemoglobin molecules, thus causing anemia.
Transmax is the only resveratrol supplement whose purity, quality and strength make it suitable for human clinical trials. Every other brand contains undesirable additives or too little of the trans-resveratrol isomer to be efficacious. For this reason it is the first choice of medical school and NIH funded studies on the health benefits of this resveratrol.
Betz continues: “The data from this study adds substantially to the growing body of scientific evidence of this remarkable compounds potential health benefits. We hope that in years to come we will be able to find more applications for resveratrol and to help develop resistance against terrible diseases like malaria and thalassemia.”
To read more about resveratrol and its applications, please visit http://www.biotivia.com
Friday 14 January 2011
Resveratrol can help combat malaria
Biotivia’s Transmax and Bioforte Resveratrol Is Picked By The LiveStrong Website As Their Recommended Resveratrol And Antioxidant Supplements.
LiveStrong, one of the world’s most visited health and fitness websites, has picked Biotivia Transmax and Bioforte as recommended resveratrol brands and top antioxidants, amongst the great amount of choices available on the market.
James Betz, Biotivia founder and CEO of Biotivia said: “This recommendation comes at a time when their are hundreds of resveratrol supplements to choose from, many of which have little or no actual trans-resveratrol isomer in their product. Transmax is 98% or better trans resveratrol, and with 500mg per capsule it is the most potent and bio-available product in the market place. It has been the best selling 500mg resveratrol supplement since its introduction three years ago. Since that time it has been constantly improved. In the Consumer Lab resveratrol evaluations just published Transmax was the only 500mg supplement that passed their rigorous testing. Recently Transmax TR, a time release version of the acclaimed supplement was released.”
Transmax and Bioforte are the only resveratrol supplements whose purity, quality and strength make them suitable for human clinical trials. Every other brand contains undesirable additives or too little of the trans-resveratrol isomer to be efficacious. For this reason it is the first choice of medical school and NIH funded studies on the health benefits of this resveratrol. It is the only resveratrol supplement to be awarded Investigational Drug status by the NIH.
Biotivia’s Transmax and Bioforte were used by researchers in two highly publicised studies into resveratrol’s effect on pre-diabetes and cognitive function. Both studies, the first by the Albert Einstein Medical Center and the second by Northumberland University, returned highly positive results and have been accepted for publishing in major peer reviewed medical journals. All four of the first round of human clinical studies of resveratrol were done using Biotivia resveratrol supplements.
Betz continues: “This is a strong testament to the quality, purity and efficacy of Biotivia Transmax and Bioforte. Biotivia’s Bioforte has been the world’s best selling 250mg resveratrol supplement for over 5 years. ”
Biotivia are also working in collaboration with the University of Ferrara, in Italy, into the benefits of Resveratrol for Thalassemia sufferers, the results of which will be available next year. More human clinical trials have been done by prestigious institutions using Transmax and Bioforte than all other brands of resveratrol combined.
To read more about Bioforte and Transmax please visit http://www.biotivia.com
###
About Biotivia LLC
Biotivia was established in 1992 in Vienna, Austria as a supplier of natural raw materials and botanicals to the supplement and functional food industries and to researchers and scientific institutions worldwide. The company evolved into one of the world's leading developers and suppliers of potent nutritional supplements and skin care therapies, with most of their products centered around the use of concentrated resveratrol and complementary botanical extracts.
Biotivia presently has US offices in New York, Los Angeles, Kansas City and international offices in the UK, Spain, Austria, Denmark, Italy, Germany, Singapore, Xi'an, China and Mumbai, India.
Beyond its strong consumer base, the company currently supplies researchers, physicians and scientists at Harvard, Stanford, Yale, Georgetown, The Albert Einstein Medical Center, University of Texas, M.D. Anderson Cancer Center and the University of California. Transmax and Bioforte in particular are being explored by several major universities as a possible treatment for a variety of conditions that seriously impair the health and well being of millions of people around the world. Biotivia recently signed an agreement to supply Transmax to the University of Ferrara for use in three human clinical trials in Italy and Egypt on its possible use by Thalassemia sufferers.
Biotivia's resveratrol products, Transmax and Bioforte, have been independently assessed by Consumer Labs, the leading American quality watchdog, and were deemed both 'most potent' and 'best value'.
Most of Biotivia's other supplements have been certified Vegan by the American Vegetarian Association.
Neither Transmax nor any Biotivia product has been shown to prevent any age related diseases. Transmax is not intended to diagnose, prevent, treat or cure any disease. The statements herein have not been reviewed or approved by the US FDA. All Biotivia supplements are manufactured in state of the art FDA inspected pharmaceutical facilities in accordance with CGMP USP standards.
James Betz, Biotivia founder and CEO of Biotivia said: “This recommendation comes at a time when their are hundreds of resveratrol supplements to choose from, many of which have little or no actual trans-resveratrol isomer in their product. Transmax is 98% or better trans resveratrol, and with 500mg per capsule it is the most potent and bio-available product in the market place. It has been the best selling 500mg resveratrol supplement since its introduction three years ago. Since that time it has been constantly improved. In the Consumer Lab resveratrol evaluations just published Transmax was the only 500mg supplement that passed their rigorous testing. Recently Transmax TR, a time release version of the acclaimed supplement was released.”
Transmax and Bioforte are the only resveratrol supplements whose purity, quality and strength make them suitable for human clinical trials. Every other brand contains undesirable additives or too little of the trans-resveratrol isomer to be efficacious. For this reason it is the first choice of medical school and NIH funded studies on the health benefits of this resveratrol. It is the only resveratrol supplement to be awarded Investigational Drug status by the NIH.
Biotivia’s Transmax and Bioforte were used by researchers in two highly publicised studies into resveratrol’s effect on pre-diabetes and cognitive function. Both studies, the first by the Albert Einstein Medical Center and the second by Northumberland University, returned highly positive results and have been accepted for publishing in major peer reviewed medical journals. All four of the first round of human clinical studies of resveratrol were done using Biotivia resveratrol supplements.
Betz continues: “This is a strong testament to the quality, purity and efficacy of Biotivia Transmax and Bioforte. Biotivia’s Bioforte has been the world’s best selling 250mg resveratrol supplement for over 5 years. ”
Biotivia are also working in collaboration with the University of Ferrara, in Italy, into the benefits of Resveratrol for Thalassemia sufferers, the results of which will be available next year. More human clinical trials have been done by prestigious institutions using Transmax and Bioforte than all other brands of resveratrol combined.
To read more about Bioforte and Transmax please visit http://www.biotivia.com
###
About Biotivia LLC
Biotivia was established in 1992 in Vienna, Austria as a supplier of natural raw materials and botanicals to the supplement and functional food industries and to researchers and scientific institutions worldwide. The company evolved into one of the world's leading developers and suppliers of potent nutritional supplements and skin care therapies, with most of their products centered around the use of concentrated resveratrol and complementary botanical extracts.
Biotivia presently has US offices in New York, Los Angeles, Kansas City and international offices in the UK, Spain, Austria, Denmark, Italy, Germany, Singapore, Xi'an, China and Mumbai, India.
Beyond its strong consumer base, the company currently supplies researchers, physicians and scientists at Harvard, Stanford, Yale, Georgetown, The Albert Einstein Medical Center, University of Texas, M.D. Anderson Cancer Center and the University of California. Transmax and Bioforte in particular are being explored by several major universities as a possible treatment for a variety of conditions that seriously impair the health and well being of millions of people around the world. Biotivia recently signed an agreement to supply Transmax to the University of Ferrara for use in three human clinical trials in Italy and Egypt on its possible use by Thalassemia sufferers.
Biotivia's resveratrol products, Transmax and Bioforte, have been independently assessed by Consumer Labs, the leading American quality watchdog, and were deemed both 'most potent' and 'best value'.
Most of Biotivia's other supplements have been certified Vegan by the American Vegetarian Association.
Neither Transmax nor any Biotivia product has been shown to prevent any age related diseases. Transmax is not intended to diagnose, prevent, treat or cure any disease. The statements herein have not been reviewed or approved by the US FDA. All Biotivia supplements are manufactured in state of the art FDA inspected pharmaceutical facilities in accordance with CGMP USP standards.
Subscribe to:
Posts (Atom)